Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
C11orf30
REST API REST API
Homo sapiens
C11orf30 is differentially expressed in 254 experiments: 120 organism parts: liver, skin, ... (118 more);, 130 disease states: normal, control, ... (128 more);, 86 cell types 330 cell lines 40 compound treatments and 71 other conditions.
Synonyms EMSY
Orthologs C11orf30 (Bos taurus)   D4AC97_RAT (Rattus norvegicus)   2210018M11Rik (Mus musculus)   C11orf30 (Gallus gallus)   ENSCING00000006315 (Ciona intestinalis)   C10H11orf30 (Danio rerio)   CG15356 (Drosophila melanogaster)   c11orf30 (Xenopus laevis)   C11orf30 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA repair, regulation of transcription, DNA-dependent, nucleus, chromatin modification
InterPro Term ENT_N
UniProt Accession B7ZKU2, B7ZKU0, Q17RM7, B4E247, Q7Z589, B7ZKT8, E9PPE6, E9PMC9, F5H2F0
Search EB-eye ENSG00000158636
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, ... (32 experiments)

Factor Value U/D Experiments
T84
2
E-GEOD-1474, E-MTAB-37
A549
2
E-GEOD-3202, E-GEOD-6013
HepG2
1
2
E-MTAB-37, E-GEOD-21154, E-GEOD-7307
MCF-7
1
2
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
JM1
1
E-MTAB-37
Met5A
1
E-GEOD-6013
324 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (42 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-26672, E-GEOD-3920
plasma cell
2
E-GEOD-6691, E-MEXP-2360
centroblast
2
E-GEOD-15271, E-TABM-702
monocyte
1
2
E-GEOD-11755, E-GEOD-22373, E-GEOD-5099
hematopoietic stem cell
1
E-MEXP-1403
chondrocyte
1
E-TABM-130
80 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-2069, E-GEOD-1577, E-MEXP-2280, ... (48 experiments)

Factor Value U/D Experiments
control
1
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363, E-GEOD-16728
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
septic shock
2
E-GEOD-8121, E-GEOD-9692
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
rhabdomyosarcoma
2
E-MTAB-62, E-MTAB-37
neurological disease, non-inflammatory
1
E-MTAB-69
124 more value(s).


Compound treatment

studied in E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (27 experiments)

Factor Value U/D Experiments
glucose
1
E-MEXP-941
untreated
1
E-GEOD-15389
control - interferon-gamma
1
E-GEOD-7216
CNOT7+CNOT8
1
E-MEXP-2218
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
34 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
76
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-MEXP-1251, E-GEOD-21374, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (6 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-26, E-MTAB-69, E-MEXP-2280, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-TABM-763, E-GEOD-3494, E-GEOD-17476, E-TABM-868, E-TABM-601, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-MEXP-2657, E-TABM-127, E-GEOD-20540, E-GEOD-20504, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-GEOD-16363, E-GEOD-430, ... (25 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (6 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-17636, E-MEXP-1403

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

Sex
studied in E-GEOD-19069, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-15799, ... (6 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.346 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM